HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis - University of Regensburg Publication Server

URN to cite this document:: urn:nbn:de:bvb:355-epub-445677
DOI to cite this document:: 10.5283/epub.44567

Werner, Jens M.

; Hornung, Matthias ; Krah, Rubertha ; Götz, Markus ; Schnitzbauer, Andreas A. ; Schlitt, Hans J.

; Geissler, Edward K.

; the International SiLVER study group, .

Preview

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
(831kB)

Date of publication of this fulltext: 26 Jan 2021 18:21

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Wiley.

Details

Preview

Indexed in

Export bibliographical data

Abstract

Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV+ subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding HCC outcome after LTx. Control ...